Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a protein derived from vitamin d tame chronic inflammation?

NCT ID NCT06877364

Disease control Sponsor: S.LAB (SOLOWAYS) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a protein called GcMAF, which is made from vitamin D-binding protein and is thought to calm the immune system. Researchers gave it to 120 adults with chronic inflammatory conditions like rheumatoid arthritis or cystitis that didn't improve with standard treatments. The goal was to check if it's safe and if it can reduce inflammation, measured by blood markers and disease activity scores.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GcMAF (a protein derived from vitamin D-binding protein that activates immune cells)
What this could lead to
If successful, this could point toward a new treatment option for people with chronic inflammatory diseases who haven't responded to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not confirm effectiveness or safety in larger populations. The treatment is experimental and may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

120 people

The number who actually took part.

Started

Sep 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion criteria * Age ≥ 18 years, informed consent. * Confirmed diagnosis of a chronic inflammatory disease (e.g., moderate rheumatoid arthritis or chronic cystitis, or another validated nosology) according to recognized criteria. * Insufficient effect or intolerance of standard anti-inflammatory therapy (NSAIDs, GCS, etc.). * Ability to comply with the study protocol. Exclusion Criteria: * Pregnancy, lactation (lack of safety data in this group). * Severe systemic diseases (liver/renal failure, severe cardiovascular diseases, uncontrolled arterial hypertension). * Active serious infections (HIV, tuberculosis, hepatitis B/C in the active phase). * Previous participation in other experimental studies \< 3 months ago. * Severe allergy to protein components of the drug.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic cystitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic cystitis Inflammation inflammatory disease rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inflammation

Contacts and locations

Locations

  • Center For New Medical Technologies

    Novosibirsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.